Pharminent

Biosimilar immunogenicity studies produce no surprises

MADRID (FRONTLINE MEDICAL NEWS) – Two biosimilar tumor necrosis factor inhibitor (TNFi) products are no more immunogenic than their reference biologic counterparts in patients with rheumatoid arthritis (RA), according to the results of two studies presented at the European Congress of Rheumatology. Results of one study, which involved 544 RA patients, showed 33.1% treated with […] http://www.pm360online.com/biosimilar-immunogenicity-studies-produce-no-surprises/

Filed under: Biosimilar